



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



A multiparametric score for assessing the individual risk of severe Covid-19 among patients with Multiple Sclerosis

Marta Ponzano^{a,*}, Irene Schiavetti^a, Francesca Bovis^a, Doriana Landi^b, Luca Carmisciano^a, Nicola De Rossi^c, Cinzia Cordioli^c, Lucia Moiola^d, Marta Radaelli^e, Paolo Immovilli^f, Marco Capobianco^g, Margherita Monti Bragadin^h, Eleonora Coccoⁱ, Cinzia Scandellari^j, Paola Cavalla^k, Ilaria Pesci^l, Paolo Confalonieri^m, Paola Periniⁿ, Roberto Bergamaschi^o, Matilde Inglese^{p,q}, Maria Petracca^{r,s}, Maria Trojano^t, Gioacchino Tedeschi^u, Giancarlo Comi^v, Mario Alberto Battaglia^{w,x}, Francesco Patti^{y,z}, Yara Dadalti Fragoso^{aa}, Sedat Sen^{ab}, Aksel Siva^{ac}, Rana Karabudak^{ad}, Husnu Efendi^{ae}, Roberto Furlan^{af}, Marco Salvetti^{ag,ah}, Maria Pia Sormani^{a,q,†}

^a Department of Health Sciences, University of Genoa, Genoa, Italy

^b Multiple Sclerosis Clinical and Research Unit, Department of Systems Medicine, Tor Vergata University, Rome, Italy

^c Centro Sclerosi Multipla ASST Spedali Civili di Brescia, Montichiari, Italy

^d Department of Neurology, Multiple Sclerosis Center, IRCCS Ospedale San Raffaele, Milan, Italy

^e Department of Neurology and Multiple Sclerosis Center, ASST "Papa Giovanni XXIII", Bergamo, Italy

^f Multiple Sclerosis Center, Ospedale Guglielmo da Saliceto, Piacenza, Italy

^g Regional Referral Multiple Sclerosis Centre, Department of Neurology, University Hospital San Luigi, Orbassano, Torino, Italy

^h AISM Rehabilitation Center, Italian MS Society, Genoa, Italy

ⁱ Centro Sclerosi Multipla, ATS Sardegna, Cagliari, Italy

^j IRCCS Istituto delle Scienze Neurologiche di Bologna, UOSI Riabilitazione Sclerosi Multipla, Bologna, Italy

^k MS Center, Department of Neuroscience, City of Health and Science University Hospital of Turin, Turin, Italy

^l Centro SM UOC Neurologia, Fidenza, AUSL PR, Fidenza, Italy

^m Multiple Sclerosis Centre, Neuroimmunology Department 'Carlo Besta' Neurological Institute, Milan, Italy

ⁿ Department of Neurology Multiple Sclerosis Center, University of Padua, Padova, Italy

^o Multiple Sclerosis Research Center, IRCCS Mondino Foundation, Pavia, Italy

^p Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINO GMI), University of Genoa, Genoa, Italy

^q IRCCS Ospedale Policlinico San Martino, Genoa, Italy

^r Department of Neurosciences and Reproductive and Odontostomatological Sciences, University of Naples Federico II, Naples, Italy

^s IRCCS Ospedale Policlinico San Martino, Genoa, Italy

^t Department of Basic Medical Sciences, Neurosciences and Sense Organs, University of Bari, Bari, Italy

^u Department of Advanced Medical and Surgical Sciences, University of Campania "L. Vanvitelli", Naples, Italy

^v Institute of Experimental Neurology, IRCCS Ospedale San Raffaele, Milano

^w Research Department, Italian Multiple Sclerosis Foundation, Genoa, Italy

^x Department of Life Sciences, University of Siena, Italy

^y Department of Medical and Surgical Sciences and Advanced Technologies, GF Ingrassia, University of Catania

^z Centro Sclerosi Multipla, Policlinico Catania, University of Catania

^{aa} Post Graduate Studies, Universidade Metropolitana de Santos, Santos, SP, Brazil

^{ab} Ondokuz Mayıs University School of Medicine Samsun, Turkey

^{ac} Istanbul University Cerrahpasa School of Medicine Istanbul, Turkey

^{ad} Hacettepe University School of Medicine Ankara, Turkey

^{ae} Kocaeli University School of Medicine Kocaeli, Turkey

^{af} Division of Neuroscience, Italian Neuroimmunology Association-AINI, IRCCS Ospedale San Raffaele, Institute of Experimental Neurology, Milano, Italy

^{ag} Department of Neuroscience, Mental Health and Sensory Organs, Sapienza University of Rome, Rome, Italy

^{ah} Unit of Neurology, IRCCS Neuromed, Pozzilli, Isernia, Italy

* Corresponding author at: Department of Health Sciences, University of Genoa, Genoa, Italy.

E-mail address: ponzano.marta@gmail.com (M. Ponzano).

† The South American MS Study Group, The Turkish MS Study Group and The Italian MuSC-19 Study Group, are the three study groups involved in this work.

ARTICLE INFO

Keywords:

Multiple Sclerosis
 Covid-19 severity
 Risk assessment score

ABSTRACT

Background: Many risk factors for the development of severe forms of Covid-19 have been identified, some applying to the general population and others specific to Multiple Sclerosis (MS) patients. However, a score for quantifying the individual risk of severe Covid-19 in patients with MS is not available. The aim of this study was to construct such score and to evaluate its performance.

Methods: Data on patients with MS infected with Covid-19 in Italy, Turkey and South America were extracted from the Musc-19 platform. After imputation of missing values, data were separated into training data set (70%) and validation data set (30%). Univariable logistic regression models were performed in the training dataset to identify the main risk factors to be included in the multivariable logistic regression analyses. To select the most relevant variables we applied three different approaches: (1) multivariable stepwise, (2) Lasso regression, (3) Bayesian model averaging. Three scores were defined as the linear combination of the coefficients estimated in the models multiplied by the corresponding value of the variables and higher scores were associated to higher risk of severe Covid-19 course. The performances of the three scores were compared in the validation dataset based on the area under the ROC curve (AUC) and an optimal cut-off was calculated in the training dataset for the score with the best performance. The probability of showing a severe Covid-19 course was calculated based on the score with the best performance.

Results: 3852 patients were included in the study (2696 in the training dataset and 1156 in the validation data set). 17% of the patients required hospitalization and risk factors for severe Covid-19 course were older age, male sex, living in Turkey or South America instead of living in Italy, presence of comorbidities, progressive MS, longer disease duration, higher Expanded Disability Status Scale, Methylprednisolone use and anti-CD20 treatment. The score with the best performance was the one derived using the Lasso selection approach (AUC= 0.72) and it was built with the following variables: age, sex, country, BMI, presence of comorbidities, EDSS, methylprednisolone use, treatment. An excel spreadsheet to calculate the score and the probability of severe Covid-19 is available at the following link: https://osf.io/ac47u/?view_only=691814d57b564a34b3596e4fcdcf8580.

Conclusions: The originality of this study consists in building a useful tool to quantify the individual risk for Covid-19 severity based on patient's characteristics. Due to the modest predictive ability and to the need of external validation, this tool is not ready for being fully used in clinical practice to make important decisions or interventions. However, it can be used as an additional instrument to identify high-risk patients and persuade them to take important measures to prevent Covid-19 infection (i.e. getting vaccinated against Covid-19, adhering to social distancing, and using of personal protection equipment).

1. Introduction

Since the start of the Covid-19 pandemic many risk factors for the development of severe forms of the disease have been identified including older age, male gender and presence of comorbidities (World Health Organization 2020a, 2020b; Zhu et al., 2020; Gao et al., 2021).

Patients with Multiple Sclerosis (MS) are in general more vulnerable and at higher risk of infections compared to the general population and Covid-19 has raised additional concern for these patients, especially for those under disease-modifying therapies (Montgomery et al., 2013; Winkelmann et al., 2016; Sormani et al., 2021). Among Italian patients with MS the risk of severe Covid-19 course was found to be two times higher compared to the general population (Sormani et al., 2021) and MS-specific risk factors for severe Covid-19 course have been identified in many studies, including higher EDSS, progressive phenotype, disease duration, corticosteroid use within 1 month since Covid-19 onset and anti-CD20 therapy (Etemadifar et al., 2021; Schiavetti et al., 2022).

Several COVID-19 severity indexes have been already developed in order to identify patients at higher-risk of hospitalization, admission to intensive care unit (ICU) and death (Huespe et al., 2022; Zhao et al., 2020; Chen et al., 2021).

However, at the present time, it does not exist such a specific score for patients with MS. The aim of this study was thus to develop a prognostic score for helping clinicians to assess the individual risk of their patients. The score was developed taking into consideration both the general and MS-specific subjects' characteristics and internal validation was conducted. The TRIPOD statement for transparent reporting of a multivariable prediction model for individual prognosis was followed (Collins et al., 2015)

2. Methods

Data on MS patients who got infected with Covid-19 in Italy, Turkey and South America were extracted from the web-based platform (Musc-

19 project) containing clinician-reported data from several MS centers around the world. Details on data sharing agreements, ethical committee approval and type of variables collected have been already reported elsewhere (Sormani et al., 2021). We reported details on the location of the participating centers in Supplementary Table 1. The presence of comorbidities was evaluated as the recording of at least one the following underlying pathologies: cerebrovascular disease, hematological disease, coronary heart disease, hypertension, diabetes, chronic liver disease, chronic kidney disease, malignant tumor, HBV, HIV, major depressive disorder, other (if specified). We excluded patients with suspected Covid-19 but without a positive Covid-19 test result and the patients enrolled in the first three months of pandemic due to the low reliability of the data collected at the beginning of the pandemic. Only patients enrolled between May 2020 and the end of the study (17 September 2021) were thus included.

2.1. Statistical analysis

Demographic and MS characteristics of the patients were presented as frequencies (%), mean (standard deviation) or median (interquartile range). Due to the presence of missing values, we performed a multiple imputation (MI) by chained equations approach with 10 imputations. After multiple imputation was performed, 10 separate datasets were created and the analyses were conducted based on theoretical rules of MI (StataCorp, 2021). In the imputation models, in addition to the variables with missing values (age, smoking habits, type of MS, disease duration and EDSS), we included as predictors sex, country, BMI and type of treatment based on the relevance of these variables in the characterization of the patients.

Subsequently, we separated the data into a training data set (70%) and a validation data set (30%) based on random computer generation. To verify the comparability of the two data sets, characteristics of the patients in the two data sets were compared using Chi-squared test or Fisher's exact test for categorical variables and Mann-Whitney U test for

continuous variables.

Univariable logistic regression models were performed in the training data set in order to identify discriminating factors between mild and severe course of Covid-19 (mild vs hospitalization or death) and the multivariable model was performed excluding the variables showing a p-value ≥ 0.10 in the univariable analysis and also MS type and disease duration due to collinearity issues. Subsequently, we reincluded the non-significant univariate predictors and we applied three different approaches for selecting the most relevant variables based on the following strategies:

- Model 1 - multivariable stepwise selection approach followed by multivariable logistic regression model with 500 bootstrap replications on the selected variables.
- Model 2 - Lasso regression selection approach followed by multivariable logistic regression model with 500 bootstrap replications on the selected variables (Tibshirani, 1996). The optimal value of the penalty parameter was determined using 10-folds Cross-validation
- Model 3 - Bayesian model averaging (BMA) approach (Hoeting et al., 1999) for logistic regression models with Covid-19 severity as dependent variable. BMA computation was performed using the R Bayesian adaptive sampling (BAS) package BAS, assigning equal probabilities to all models in order to not make any a priori assumptions. Factors with posterior inclusion probability (PIP) ≥ 0.7 were selected.

The coefficients estimated in the models were used to derive three scores, defined as the linear combination of the coefficients multiplied by the corresponding value of the p variables (Score = β₁ × var₁ + β₂ × var₂ + . . . + β_p × var_p) and higher scores represented a greater risk of severe Covid-19 course.

The discriminating performance of the three scores was evaluated in the validation set as the area under the ROC curve (AUC). For the score with the best performance we identified in the training data set an optimal cut-off based on the Liu criterion, which consists in maximizing the product of sensitivity and specificity (Liu, 2012). The Liu criterion is appropriate in this context since it allows to find an optimal cut-point to dichotomize a continuous variable based on sensitivity as well as specificity. Additionally, as a sensitivity analysis, we also estimated the optimal cut-off as the cut point on the ROC curve closest to (0,1) and using the Youden method but the estimated cut points were very similar (Liu: 3.02, nearest to (0,1): 3.10; Youden: 3.32). Subsequently, in the validation sample we derived sensitivity, specificity and their corresponding 95% confidence intervals (CI) to assess the performance of the binary score. For the model with the best performing, we also estimated the probability of showing a severe Covid-19 outcome based on the estimated coefficients as follows:

$$\text{Probability of severe disease} = \frac{e^{\beta_0 + \beta_1 \text{ var}_1 + \dots + \beta_p \text{ var}_p}}{1 + e^{\beta_0 + \beta_1 \text{ var}_1 + \dots + \beta_p \text{ var}_p}}$$

All statistical analyses and multiple imputation were performed using Stata version 16.0 (Stata Corporation, College Station, TX, USA) except for the BMA (R v3.5).

3. Results

Out of the 4820 patients from Italy, Turkey and South America enrolled into the Musc-19 platform at the cutoff date of 17 September 2021, 3852 patients remained after applying the exclusion criteria (Fig. 1).

Descriptive characteristics of the included patients (N=3852) are reported in Table 1, together with the rate of missing data for each variable. Before imputing data, the missing rate ranged from 0% to 11%. Patients were principally from Turkey (51%) and Italy (47%) while only 2% of the patients were from South American countries. The median age was 40 years (IQR=32-49), 69% of the patients were females




Fig. 1. Flowchart of patient inclusion and exclusion.

and most of them (86%) had no comorbidities. Only 12% of the patients were in a progressive phase and the median EDSS was 2 (IQR=1-3). 3440 patients (89%) were treated at the time of Covid-19 onset and the most used disease modifying therapies were Fingolimod (16%) and anti-CD20 (Ocrelizumab and Rituximab, 15%). After splitting the data into training data set (70%, N=2696) and validation data set (30%, N=1156), the training and validation samples resulted comparable for all the variables (Table 1).

Most of the patients had a mild Covid-19 course (83%) and among those who showed a severe course only 77(2%) died or were admitted to ICU. Univariable and multivariable analysis evaluating factors associated with a risk of a severe Covid-19 are reported in Table 2. Older age, male sex, living in Turkey or South America instead of living in Italy, presence of comorbidities, higher Expanded Disability Status Scale (EDSS), Methylprednisolone use and anti-CD20 treatment were found to be risk factors with a significant effect on the risk of severe Covid-19, confirming some previous findings. Additionally, based on the univariable results, patients with progressive MS or with a longer disease duration were at higher risk of severe Covid-19 while patients under Interferon were at lower risk of severe Covid-19 course.

Coefficients (log of the odds ratio) and standard errors derived from the three models are reported in Table 3. The variables included in the three models were largely overlapping, excluding BMI and treatment with interferon (included only in Model 2) and for Methylprednisolone use (not included in Model 3).

Performances of the three models were reported in Table 4. The inclusion of MS characteristics in the definition of the scores only slightly improved the performance. The highest AUC in the validation set was observed for the second model (AUC=0.72). However, the performance of the other models was only slightly poorer compared to Model 2, which was also the less parsimonious in terms of number of variables. The selected score (Score=0.04*Age+0.42*Male sex+1.00*Living in Turkey instead of Italy+1.33*Living in South America instead of Italy+0.01*BMI+0.76*Presence of comorbidities+0.11*EDSS+0.83*Methylprednisolone use-0.34*Interferon Treatment+0.42*Anti-CD20 Treatment) ranged from 0.94 to 6.05 in the validation set, with a median of 2.90.

The optimal cut-point for the score was found to be 3.02 and patients were classified as having higher risk of severe Covid-19 if their score was higher than 3.02. The application of this cut-off in the validation sample yielded a sensitivity of 68% and a specificity of 59% (Table 5).

Estimated probabilities of severe Covid-19 ranged from 0.02 to 0.89, with an observed mean of 0.17 (standard deviation=0.13).

To facilitate the application of the score in daily practice, an excel spreadsheet that enables the data entry of the patient characteristics and the automatic calculation of the score and of the estimated probability of severe disease can be downloaded at the following link: https://osf.io/ac47u/?view_only=691814d57b564a34b3596e4fcdcf8580

4. Discussion

In this work, we identified several risk factors for severe Covid-19, some related to general characteristics and others specific to MS.

Table 1

Characteristics of the patients in the original sample and after imputation, splitting into training data set (70%) and validation data set (30%). The developmental and validation samples were comparable for all the variables.

	Original Sample	Missing	After Imputation N=3852	Training N=2696	Validation N=1156
General characteristics					
Age, mean(SD)	40.9(11.9)	85(2%)	40.9(11.8)	40.7(11.9)	41.3(11.6)
Male, N(%)	1198(31%)	0(0%)	1198(31%)	826(31%)	372(32%)
Country, N(%)					
Italy	1805(47%)	0(0%)	1805(47%)	1283(48%)	522(45%)
Turkey	1961(51%)		1961(51%)	1357(50%)	604(52%)
South America	86(2%)		86(2%)	56(2%)	30(3%)
Healthcare Job, N(%)	295(8%)	0(0%)	295(8%)	212(8%)	83(7%)
Smoking, N(%)					
Never	2446(71%)	424(11%)	2682(70%)	1867(69%)	815(71%)
Former	478 (14%)		666(17%)	471(17%)	195(17%)
Current	504(15%)		504(13%)	358(13%)	146(13%)
BMI, mean(SD)	24.7(5.5)	0(0%)	24.7(5.5)	24.7(5.6)	24.7(5.4)
Presence of comorbidities, N(%)	522(14%)	0(0%)	522(14%)	362(13%)	160(14%)
MS related characteristics					
MS Type, N(%)					
RRMS	3300(88%)	102(3%)	3381(88%)	2376(88%)	1005(87%)
PPMS	154(4%)		173(4%)	124(5%)	49(4%)
SPMS	296(8%)		298(8%)	196(7%)	102(9%)
Disease Duration, mean(SD)	8.5(7.5)	40(1%)	8.5(7.5)	8.5(7.5)	8.6(7.4)
EDSS, median(IQR)	2(1-3)	366(10%)	2(1-3)	2(1-3)	2(1-3)
Methylprednisolone, N(%)	85(2%)	0(0%)	85(2%)	61(2%)	24(2%)
Treatment, N(%)					
None	412(11%)	0(0%)	412(11%)	282(10%)	130(11%)
Interferon	477(12%)		477(12%)	343(13%)	134(12%)
Copaxone	331(9%)		331(9%)	239 (9%)	92(8%)
Terifunomide	382(10%)		382(10%)	260(10%)	122(11%)
Dimethyl fumarate	532(14%)		532(14%)	358(13%)	174(15%)
Natalizumab	332(9%)		332(9%)	231(9%)	101(9%)
Fingolimod	620(16%)		620(16%)	424(16%)	196(17%)
Anti-CD20	576(15%)		576(15%)	417(15%)	159(14%)
Other	190(5%)		190(5%)	142(5%)	48(4%)

Table 2

Comparisons of characteristics between patients with mild and patients with severe (hospitalization or death) Covid-19 infection and results of the univariable and multivariable logistic regression models. Only variables showing p-value<0.10 in the univariable analysis were included in the multivariable model and MS type and disease duration were not included due to collinearity issues. The analyses were performed on the training data (N=2696) and odds ratios for age, BMI and disease duration refer to the 10-unit increase.

	Mild Covid-19 N=2235 (83%)	Severe Covid-19 N=461 (17%)	Univariable OR (95% CI)	p-value	Multivariable OR (95% CI)	p-value
General characteristics						
Age, mean(SD)	39.6(11.3)	46.1(13.4)	1.6(1.5-1.7)	<0.001	1.5(1.3-1.6)	<0.001
Male, N(%)	652(29%)	174(38%)	1.5(1.2-1.8)	<0.001	1.5(1.2-1.9)	<0.001
Country						
Italy	1117(50%)	166(36%)	—	—	—	—
Turkey	1081(48%)	276(60%)	1.7(1.4-2.1)	<0.001	2.7(2.1-3.5)	<0.001
South America	37(2%)	19(4%)	3.5(1.9-6.2)	<0.001	3.8(2.0-7.2)	<0.001
Healthcare Job, N(%)	181(8%)	31(7%)	0.8(0.6-1.2)	0.319	—	—
Smoking, N(%)						
Never	1552(69%)	315(68%)	—	—	—	—
Former	380(17%)	91(20%)	1.2(0.9-1.5)	0.210	—	—
Current	303(14%)	55(12%)	0.9(0.7-1.2)	0.483	—	—
BMI, mean(SD)	24.5(5.6)	25.6(5.2)	1.4(1.2-1.6)	<0.001	1.1(0.9-1.3)	0.237
Presence of comorbidities, N (%)	239 (11%)	123(27%)	3.0(2.4-3.9)	<0.001	2.1(1.6-2.9)	<0.001
MS related characteristics						
MS Type, N(%)						
RRMS	2032(91%)	344(75%)	—	—	—	—
PPMS	76(3%)	48(10%)	3.7(2.6-5.4)	<0.001	—	—
SPMS	127(6%)	69(15%)	3.2(2.3-4.4)	<0.001	—	—
Disease Duration, mean(SD)	8.2(7.3)	9.9(8.4)	1.3(1.2-1.5)	<0.001	—	—
EDSS, median(IQR)	1.5(1-3)	2.5(1-4.5)	1.3(1.2-1.4)	<0.001	1.1(1.0-1.2)	0.001
Methylprednisolone, N(%)	41(2%)	20(4%)	2.4(1.4-4.2)	0.001	2.3(1.3-4.2)	0.006
Treatment, N(%)						
None or Other	1635(73%)	301(65%)	—	—	—	—
Interferon	305(14%)	38(8%)	0.7(0.5-1.0)	0.033	0.7(0.5-1.1)	0.100
Anti-CD20	295(13%)	122(26%)	2.2(1.8-2.9)	<0.001	1.5(1.1-2.0)	0.004

Table 3

Estimates of coefficients (β) and standard errors (SE) after applying three approaches for selecting the relevant variables to discriminate patients with mild vs severe Covid-19 course. The initial set of variables consisted of the variables included in the multivariable logistic regression model and all the analyses were performed on the training dataset (N=2696). For Model 1 and Model 2, stepwise and lasso regressions with 10-fold cross-validation were respectively used as selection approaches, followed by 500 bootstrap replications and, additionally, lasso penalized coefficients have been shown; Model 3 consisted of Bayesian model averaging (BMA) and variables were selected based on the posterior inclusion probability (PIP \geq 0.7).

General characteristics	Model 1, Stepwise		Model 2, Lasso Penalized β	β	SE	Model 3, BMA		PIP
	β	SE				β	SE	
Age	0.04	0.01	0.04	0.04	0.01	0.04	0.01	1.00
Male	0.42	0.11	0.41	0.42	0.11	0.41	0.13	0.97
Country								
Turkey	1.01	0.12	0.99	1.00	0.12	1.02	0.13	1.00
South America	1.33	0.36	1.32	1.33	0.36	1.34	0.34	0.99
Healthcare Job	x	x	x	x	x	x	x	0.06
Current of former Smoker	x	x	x	x	x	x	x	0.05
BMI	x	x	0.01	0.01	0.01	x	x	0.09
Presence of comorbidities	0.78	0.14	0.76	0.76	0.15	0.78	0.15	1.00
MS related characteristics								
EDSS	0.12	0.03	0.11	0.11	0.03	0.13	0.04	0.98
Methylprednisolone 1 month before Covid Treatment	0.84	0.32	0.83	0.83	0.32	x	x	0.62
Interferon	x	x	-0.31	-0.34	0.20	x	x	0.21
Anti-CD20	0.46	0.16	0.42	0.42	0.16	0.36	0.22	0.81

Table 4

Area under the ROC Curve (95%CI) for evaluating the performance of the three scores in discriminating between mild and severe Covid-19 infections, based on just the general characteristics of the patients and on both general and MS characteristics. The analyses were performed on the validation dataset (N=1156).

	Score 1	Score 2	Score 3
General characteristics	0.70(0.66-0.74)	0.70(0.66-0.74)	0.70(0.66-0.74)
General + MS characteristics	0.71(0.67-0.75)	0.72 (0.68-0.76)	0.71(0.67-0.75)

Table 5

Evaluation of the performance of the dichotomized Score 2 (cut-off=3.02) in discriminating between mild and severe Covid-19 infections in the Validation data set (N=1156). The optimal cut point was calculated in the Training data set (N=2696) based on the Liu criterion.

Sensitivity (95%CI)	Specificity(95%CI)
68%(60%-74%)	59%(56%-62%)

These results were consistent with previous findings and are thus a confirmation of what has been already shown elsewhere (Gao et al., 2021; Etemadifar et al., 2021). The originality of this study consists in building a score to quantify the individual risk of severe Covid-19 among patients with MS.

To identify the features contributing to this score, we performed three models based on different statistical approaches and results remained quite consistent: this consistency guarantees a good reliability of variables selection. Additionally, when constructing the scores, we also evaluated the contribution of the selected MS characteristics (EDSS, Methylprednisolone use, Treatment) on the performance of the scores and we observed only a slight improvement compared to those based exclusively on general characteristics. It follows that even if it is known that some characteristics of MS play a role in the severity of Covid-19, the general characteristics of the patients seem to be more relevant.

The score was found to have a modest predictive ability (AUC=0.72 and when the dichotomized score was evaluated: sensitivity=0.68, specificity=0.59). As such, the score cannot be used in clinical practice to take important decisions such as treatment changes, asking for sick leave or planning resources allocation. Additionally, even if the very large sample size of our study enabled to split the data into training and

validation datasets while still maintaining a large sample size, external validation of the score on an independent set of data is needed to further support our results before it can be fully used in practice (Altman et al., 2009).

However, before further research is done to completely validate the score and to improve its predictive ability, we suggest an initial use of the score in practice which may seem less ambitious than one would expect but that is still important. In particular, the score may be used as a useful supplementary tool for quantifying the personal risk assessment in order to give the higher-risk patients an additional reason to get vaccinated against Covid-19 if they haven't had it yet and to appropriately adhere to social distancing and use of protective equipment to decrease the risk of getting infected (Landi et al., 2020; Abbasi et al., 2022). As such, in this initial context of application, the modest predictive ability it's not of much concern and the fact that sensitivity is higher than specificity is even preferable, since it is better to identify more false positives compared to many false negatives. Additionally, in this context of application, the fact that we prospectively followed patients infected with Covid-19 prior to the start of the vaccinations programs no longer seems a limitation since the enrolled patients better reflect the patients who have hesitated to take the vaccination. To identify the patients at higher risk of severe Covid-19 course, clinicians can compare the observed score with the derived cut-off: more the observed value is higher than the threshold, more the patient is at risk while more the observed value is lower than the threshold, less the patient is at risk. Additionally, the clinician can also directly derive the estimated probability of showing a severe Covid-19 course. All these calculations (continuous score, magnitude and sign of the difference between observed value and cut-off and the estimated probability) may be used together to get a more complete understanding of the patient's risk and can be easily derived using the provided user-friendly excel spreadsheet.

Future research should also evaluate the performance of the score in other countries. Differences in hospitalizations rates among countries can indeed depend on quality and accessibility of Health Service but also on the national guidelines regarding the hospital admission of the patients (Fragoso et al., 2021; Zakaria et al., 2021). As first preliminary analysis or in the absence of studies presenting specific-region scores, for patients outside Italy, Turkey and South America, the score may be calculated on the basis of which of the three regions is the most similar to the country under study in terms of National Health Service and Covid-19 cases management. However, country-specific scores should then be defined.

Funding source

No sources.

CRediT authorship contribution statement

Marta Ponzano: Formal analysis, Methodology, Writing – original draft. **Irene Schiavetti:** Formal analysis, Methodology, Writing – original draft. **Francesca Bovis:** Formal analysis, Methodology, Writing – original draft. **Doriana Landi:** Investigation, Writing – review & editing. **Luca Carmisciano:** Investigation, Writing – review & editing. **Nicola De Rossi:** Investigation, Writing – review & editing. **Cinzia Cordioli:** Investigation, Writing – review & editing. **Lucia Moiola:** Investigation, Writing – review & editing. **Marta Radaelli:** Investigation, Writing – review & editing. **Paolo Immovilli:** Investigation, Writing – review & editing. **Marco Capobianco:** Investigation, Writing – review & editing. **Margherita Monti Bragadin:** Investigation, Writing – review & editing. **Eleonora Cocco:** Investigation, Writing – review & editing. **Cinzia Scandellari:** Investigation, Writing – review & editing. **Paola Cavalla:** Investigation, Writing – review & editing. **Iliaria Pesci:** Investigation, Writing – review & editing. **Paolo Confalonieri:** Investigation, Writing – review & editing. **Paola Perini:** Investigation, Writing – review & editing. **Roberto Bergamaschi:** Investigation, Writing – review & editing. **Matilde Inglese:** Investigation, Writing – review & editing. **Maria Petracca:** Investigation, Writing – review & editing. **Maria Trojano:** Investigation, Writing – review & editing. **Gioacchino Tedeschi:** Investigation, Writing – review & editing. **Giancarlo Comi:** Investigation, Writing – review & editing. **Mario Alberto Battaglia:** Investigation, Writing – review & editing. **Francesco Patti:** Investigation, Writing – review & editing. **Yara Dadalti Fragoso:** Investigation, Writing – review & editing. **Sedat Sen:** Investigation, Writing – review & editing. **Aksel Siva:** Investigation, Writing – review & editing. **Rana Karabudak:** Investigation, Writing – review & editing. **Husnu Efendi:** Investigation, Writing – review & editing. **Roberto Furlan:** Investigation, Writing – review & editing. **Marco Salvetti:** Investigation, Writing – review & editing. **Maria Pia Sormani:** Investigation, Writing – review & editing.

Declaration of Competing Interest

MP. Sormani reports grants from Roche, during the conduct of the study; personal fees from Biogen, Merck, Roche, Sanofi, Novartis, Medday, Geneuro, Celgene, Mylan outside the submitted work.

N. De Rossi received speaker honoraria from Biogen Idec, Genzyme, Novartis, Sanofi-Aventis; received funding for participation in advisory board to Novartis, Biogen and Genzyme-Sanofi and for travel to scientific meetings from Biogen Idec, Teva, Sanofi-Genzyme, Roche, Almirall and Novartis.

M. Radaelli received speaker honoraria from Biogen Idec, Sanofi-Genzyme, Novartis and Merck Serono and funding for travel to scientific meetings from Biogen Idec, Sanofi-Genzyme, Novartis, Merck Serono, Teva and Roche.

P. Immovilli reports personal fees from Roche, personal fees from Biogen, personal fees from Merck, outside the submitted work.

M. Capobianco reports personal fees and non-financial support from Biogen, personal fees and non-financial support from Merck Serono, personal fees and non-financial support from Roche, personal fees and non-financial support from Novartis, personal fees and non-financial support from Sanofi, personal fees from Almirall, outside the submitted work.

P. Confalonieri has received honoraria for speaking or consultation fees from Novartis and Biogen, has received funding for travel to attend scientific events or speaker honoraria from Merck Serono, Biogen Idec, Teva and Roche. He has also received institutional research support from Merck-Serono, Novartis and Roche. He is also principal investigator in clinical trials for Biogen, Merck Serono, Roche.

P Perini has received honoraria for lectures and support for attending meetings and travel from Roche, Biogen, Merck, Novartis, Sanofi, Teva

M.Inglese received research grants from NIH, DOD, NMSS, FISM, and Teva Neuroscience; received fees for participating in advisory boards from Roche, Biogen, Merck and Genzyme.

M. Trojano reports grants and personal fees from Biogen, grants and personal fees from Novartis, grants and personal fees from Roche, grants and personal fees from Merck, personal fees from Sanofi, personal fees from TEVA, from null, outside the submitted work.

G. Comi reports personal fees from Novartis, Teva Pharmaceutical Industries Ltd, Teva Italia Srl, Sanofi Genzyme, Genzyme Corporation, Genzyme Europe, Merck KGaA, Merck Serono SpA, Celgene Group, Biogen Idec, Biogen Italia Srl, F. Hoffman-La Roche, Roche SpA, Almirall SpA, Forward Pharma, Medday, Excemed, outside the submitted work.

F. Patti reports grants from Biogen, grants from Merck, grants from FISM, grants from Onlus association, grants from University of Catania, personal fees from Almirall, personal fees from Bayer, personal fees from Biogen, personal fees from Merck, personal fees from Roche, personal fees from Sanofi, personal fees from TEVA, outside the submitted work.

M. Salvetti reports grants and personal fees from Biogen, grants and personal fees from Merck, grants and personal fees from Novartis, grants and personal fees from Roche, grants and personal fees from Sanofi, grants and personal fees from Teva, grants from Italian Multiple Sclerosis Foundation, grants from Sapienza University of Rome, outside the submitted work.

I .Schiavetti received consulting fees from Hippocrates Research, NovaNeuro, Sakura Italia, ADL Farmaceutici, Associazione Commissione Difesa Vista Onlus

Supplementary materials

Supplementary material associated with this article can be found, in the online version, at doi:[10.1016/j.msard.2022.103909](https://doi.org/10.1016/j.msard.2022.103909).

References

- Abbasi, N, Ghadiri, F, Moghadasi, AN, Azimi, A, Navardi, S, Heidari, H, Karaminia, M, Sahaian, MA, 2022. COVID-19 vaccine hesitancy in Iranian patients with Multiple Sclerosis. *Mult. Scler. Relat. Disord.* 60, 103723 <https://doi.org/10.1016/j.msard.2022.103723>. Epub ahead of print. PMID: 35276452; PMCID: PMC8896865.
- Altman, DG, Vergouwe, Y, Royston, P, Moons, KGM, 2009. Prognosis and prognostic research: validating a prognostic model. *BMJ* 338 (7708), 1432–1435. <https://doi.org/10.1136/bmj.b605>. ISSN 17561833.
- Chen, Y, Zhou, X, Yan, H, Huang, H, Li, S, Jiang, Z, Zhao, J, Meng, Z., 2021. CANPT score: a tool to predict severe COVID-19 on admission. *Front. Med. (Lausanne)* 8, 608107. <https://doi.org/10.3389/fmed.2021.608107>. PMID: 33681245; PMCID: PMC7930838.
- Collins, GS, Reitsma, JB, Altman, DG, Moons, KGM, 2015. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. *BMJ* 350. <https://doi.org/10.1136/bmj.g7594>. ISSN 17561833.
- Etemadifar, M, Nouri, H, Maracy, MR, Akhavan Sigari, A, Salari, M, Blanco, Y, Sepúlveda, M, Zabalza, A, Mahdavi, S, Baratian, M, Sedaghat, N, 2021. Risk factors of severe COVID-19 in people with Multiple Sclerosis: a systematic review and meta-analysis. *Rev. Neurol. (Paris)*. <https://doi.org/10.1016/j.neurol.2021.10.003>. S0035-3787(21)00743-8Epub ahead of print. PMID: 34836608; PMCID: PMC8566345.
- Fragoso, YD, Schiavetti, I, Carmisciano, L, Ponzano, M, Steinberg, J, Treviño-Frenk, I, Ciampi, E, Vecino, MCA, Correa, EP, Carcamo, C, Gomes, S, Pimentel, MLV, Santos, GAC, Vrech, C, Winckler, TCA, Sormani, MP, 2021. Coronavirus disease 2019 in Latin American patients with Multiple Sclerosis. *Mult. Scler. Relat. Disord.* 55, 103173 <https://doi.org/10.1016/j.msard.2021.103173>. Epub 2021 Jul 25. PMID: 34332462; PMCID: PMC8310568.
- Gao, YD, Ding, M, Dong, X, Zhang, JJ, Kursat Azkur, A, Azkur, D, Gan, H, Sun, YL, Fu, W, Li, W, Liang, HL, Cao, YY, Yan, Q, Cao, C, Gao, HY, Brügger, MC, van de Veen, W, Sokolowska, M, Akdis, M, Akdis, CA, 2021. Risk factors for severe and critically ill COVID-19 patients: a review. *Allergy* 76 (2), 428–455. <https://doi.org/10.1111/all.14657>. Epub 2020 Dec 4. PMID: 33185910.
- Hoeting, JA, Madigan, D, Raftery, AE, et al., 1999. Bayesian model averaging: a tutorial. *Stat. Sci.* 14, 382–417.
- Huespe, I, Carboni Bisso, I, Di Stefano, S, Terrasa, S, Gemelli, NA, Las Heras, M, 2022. COVID-19 severity index: a predictive score for hospitalized patients. *Med. Intensiva* 46 (2), 98–101 (English Edition), [VolumelssuePagesISSN 2173-5727](https://doi.org/10.1016/j.medint.2021.10.003).
- Landi, D, Ponzano, M, Nicoletti, CG, Cecchi, G, Cola, G, Mataluni, G, Mercuri, NB, Sormani, MP, Marfia, GA, 2020 Oct. Adherence to social distancing and use of

- personal protective equipment and the risk of SARS-CoV-2 infection in a cohort of patients with Multiple Sclerosis. *Mult. Scler. Relat. Disord.* 45, 102359 <https://doi.org/10.1016/j.msard.2020.102359>. Epub 2020 Jul 3. PMID: 32663793; PMCID: PMC7333605.
- Liu, X., 2012. Classification accuracy and cut point selection. *Stat. Med.* 31 (23), 2676–2686. <https://doi.org/10.1002/sim.4509>. Epub 2012 Feb 3. PMID: 22307964.
- Montgomery, S, Hillert, J, Bahmanyar, S., 2013. Hospital admission due to infections in Multiple Sclerosis patients. *Eur. J. Neurol.* 20 (8), 1153–1160. <https://doi.org/10.1111/ene.12130>. Epub 2013 Mar 16. PMID: 23496086.
- Schiavetti, I, Ponzano, M, Signori, A, Bovis, F, Carmisciano, L, Sormani, MP., 2022. Severe outcomes of COVID-19 among patients with Multiple Sclerosis under anti-CD-20 therapies: a systematic review and meta-analysis. *Mult. Scler. Relat. Disord.* 57, 103358 <https://doi.org/10.1016/j.msard.2021.103358>. Epub 2021 Nov 5. PMID: 35158467.
- Sormani, MP, De Rossi, N, Schiavetti, I, Carmisciano, L, Cordioli, C, Moiola, L, Radaelli, M, Immovilli, P, Capobianco, M, Trojano, M, Zaratini, P, Tedeschi, G, Comi, G, Battaglia, MA, Patti, F, Salvetti, M, Musc-19 Study Group, 2021. Disease-modifying therapies and coronavirus disease 2019 severity in Multiple Sclerosis. *Ann. Neurol.* 89 (4), 780–789. <https://doi.org/10.1002/ana.26028>. Epub 2021 Feb 9. PMID: 33480077; PMCID: PMC8013440.
- Sormani, MP, Schiavetti, I, Carmisciano, L, Cordioli, C, Filippi, M, Radaelli, M, Immovilli, P, Capobianco, M, De Rossi, N, Bricchetto, G, Cocco, E, Scandellari, C, Cavalla, P, Pesci, I, Zito, A, Confalonieri, P, Marfia, GA, Perini, P, Inglese, M, Trojano, M, Brescia Morra, V, Tedeschi, G, Comi, G, Battaglia, MA, Patti, F, Salvetti, M, MuSC-19 Study Group, 2021. COVID-19 severity in Multiple Sclerosis: putting data into context. *Neurol. Neuroimmunol. Neuroinflamm.* 9 (1), e1105. <https://doi.org/10.1212/NXI.0000000000001105>. PMID: 34753829; PMCID: PMC8579249.
- StataCorp, 2021. *Stata: Release 17. Statistical Software.* StataCorp LLC, College Station, TX.
- Tibshirani, R., 1996. Regression shrinkage and selection via the lasso. *J. R. Stat. Soc. Ser. B (Methodol.)* 267–288.
- Winkelmann, A, Loebermann, M, Reisinger, EC, Hartung, HP, Zettl, UK, 2016. Disease-modifying therapies and infectious risks in Multiple Sclerosis. *Nat. Rev. Neurol.* 12 (4), 217–233. <https://doi.org/10.1038/nrneuro.2016.21>. Epub 2016 Mar 4. PMID: 26943779.
- World Health Organization, 2020b. WHO Director-General's opening remarks at the media briefing on COVID-19 - 11 March 2020. WHO Director-General's Opening Remarks at the Media Briefing on COVID-19. World Health Organization. <https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19-11-march-2020>. accessed 21 January 2022.
- World Health Organization, 2020a. Health topics: Coronavirus disease (COVID-19). Health Topics: Coronavirus Disease (COVID-19). World Health Organization accessed 21 January 2022.
- Zakaria, M, Ponzano, M, Schiavetti, I, Carmisciano, L, Nada, M, AbdelNaseer, M, Zamzam, D, Masoud, J, Aref, H, Shalaby, N, AbdelNaser, A, Hamdy, S, Saad, M, Shehata, H, Aly, M, Kishk, N, Hamdy, E, Hassan, A, Hashish, A, Ahmed, S, Foad, M, Sormani, MP, 2021. The MuSC-19 study: the Egyptian cohort. *Mult. Scler. Relat. Disord.* 56, 103324 <https://doi.org/10.1016/j.msard.2021.103324>. Epub 2021 Oct 10. PMID: 34656933; PMCID: PMC8522261.
- Zhao, Z, Chen, A, Hou, W, Graham, JM, Li, H, Richman, PS, et al., 2020. Prediction model and risk scores of ICU admission and mortality in COVID-19. *PLoS One* 15 (7), e0236618.
- Zhu, N, Zhang, D, Wang, W, et al., 2020. A novel coronavirus from patients with pneumonia in China, 2019. *N. Engl. J. Med.* 382 (8), 727–733. <https://doi.org/10.1056/NEJMo a2001017>.